Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1 H-indol-1-yl]pyridine-2-yl}propanoic Acid
AstraZeneca, Sweden; Shaw Research, USA.
AstraZeneca, Sweden.
AstraZeneca, Sweden.
AstraZeneca, Sweden.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: ACS Medicinal Chemistry Letters, ISSN 1948-5875, E-ISSN 1948-5875, Vol. 9, nr 7, s. 600-605Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

A lead generation campaign identified indole-based sPLA2-X inhibitors with a promising selectivity profile against other sPLA2 isoforms. Further optimization of sPLA2 selectivity and metabolic stability resulted in the design of (-)-17, a novel, potent, and selective sPLA2-X inhibitor with an exquisite pharmacokinetic profile characterized by high absorption and low clearance, and low toxicological risk. Compound (-)-17 was tested in an ApoE-/- murine model of atherosclerosis to evaluate the effect of reversible, pharmacological sPLA2-X inhibition on atherosclerosis development. Despite being well tolerated and achieving adequate systemic exposure of mechanistic relevance, (-)-17 did not significantly affect circulating lipid and lipoprotein biomarkers and had no effect on coronary function or histological markers of atherosclerosis.

Ort, förlag, år, upplaga, sidor
American Chemical Society , 2018. Vol. 9, nr 7, s. 600-605
Nyckelord [en]
atherosclerosis, carotid ligation, coronary artery disease, inhibitor, Secreted phospholipase A2 type X, sPLA2-X, 2 [2 [carbamoyl 6 (trifluoromethoxy) 1h indol 1 yl]pyridine 2 yl]propanoic Acid, propionic acid derivative, unclassified drug, animal experiment, animal model, Article, carotid artery ligation, controlled study, drug absorption, drug bioavailability, drug clearance, drug design, drug potency, drug selectivity, IC50, IC90, in vitro study, in vivo study, lipophilicity, male, mouse, nonhuman, plasma protein binding, priority journal
Nationell ämneskategori
Kemiteknik
Identifikatorer
URN: urn:nbn:se:ri:diva-37293DOI: 10.1021/acsmedchemlett.7b00507Scopus ID: 2-s2.0-85049247977OAI: oai:DiVA.org:ri-37293DiVA, id: diva2:1280251
Anmärkning

Funding details: AstraZeneca

Tillgänglig från: 2019-01-18 Skapad: 2019-01-18 Senast uppdaterad: 2019-03-28Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Personposter BETA

de la Motte, Hanna

Sök vidare i DiVA

Av författaren/redaktören
de la Motte, Hanna
I samma tidskrift
ACS Medicinal Chemistry Letters
Kemiteknik

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 3 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
v. 2.35.8